Physician profile
Andrew S Dorizas
NPI 1336506260
$896,518.57
in general payments reported to CMS, 2019-2025
44 companies · $578K in 2025
The $578K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,619 · 2020: $1,741 · 2021: $2,339 · 2022: $2,840 · 2023: $55K · 2024: $255K · 2025: $578K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $616K · Consulting Fee: $131K · Travel and Lodging: $104K · Food and Beverage: $37K · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $616,068.00 |
| Consulting Fee | $130,670.02 |
| Travel and Lodging | $104,458.09 |
| Food and Beverage | $36,610.98 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $263,981.19 | 2020-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $117,887.28 | 2022-2025 | Bimzelx |
| Lilly USA, LLC | $105,755.52 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $84,504.12 | 2020-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $69,756.38 | 2023-2025 | Zoryve |
| Incyte Corporation | $56,121.70 | 2022-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $44,632.24 | 2020-2025 | Nemluvio, Epsolay |
| Pfizer INC. | $43,532.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36,557.87 | 2022-2025 | Spevigo |
| Amgen INC. | $27,879.63 | 2020-2025 | Otezla, Otezla |
| Almirall LLC | $17,205.61 | 2020-2025 | Klisyri, Seysara |
| E.R. Squibb & Sons, L.L.C. | $7,121.63 | 2021-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $4,523.02 | 2019-2025 | Dupixent |
| Genzyme Corporation | $4,159.21 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $2,647.38 | 2021-2025 | Winlevi, Absorica Ld, Blu-U |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dorizas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.